Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression

Helus Pharma reported that its deuterated psilocin therapy, HLP003, significantly reduced major depressive disorder symptoms in a late-stage trial, but its stock fell due to three undisclosed serious adverse events. The trial met primary and secondary endpoints, with a 19.5-point reduction in symptoms versus 11.9 for placebo. Analysts noted the efficacy but emphasized the need for safety clarification. The company expects further trial results in 2027.

Original reporting
Published Nov 16, 2026, 3:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 16, 2026, 4:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Serious adverse events mar robust efficacy data for Helus’ psychedelic in major depression — source image
Decision brief

The 30-second read

Med
01

Why it matters

The trade hinges on a mixed read-through: primary and key secondary efficacy endpoints appear strong versus placebo, but the company disclosed three treatment-related SAEs, including depression cases and a suicide attempt by a non-responder, which triggered a sharp selloff.

02

Market read

Strong efficacy data was not enough to offset newly disclosed serious safety events, driving a large same-day decline and increasing the probability of heightened safety-focused scrutiny.

03

What to watch

The article does not specify SAE rates, adjudication details, or whether the suicide attempt was causally linked; investors may over-discount without full safety context, and upcoming EMBRACE topline in Q4 2027 is a longer-dated catalyst.

Relevance 8/10Novelty 8/10Timing: same-day after-hours/next-session repricing following Monday’s Phase 3 SAE disclosure

Background

Helus is running a Phase 3 program (PARADIGM) for deuterated psilocin analog HLP003 in major depressive disorder, with FDA Breakthrough Therapy Designation for adjunctive MDD.

Market effects

Adds to the ongoing debate on psychedelic therapy safety, potentially increasing scrutiny and volatility across the psychedelic depression development cohort.

US biotech sentiment may soften for similar clinical-stage psychedelic names as safety signals dominate near-term trading.

Could influence international investor appetite for deuterated psilocin and related psychedelic programs, especially around FDA review expectations.

Counterpoint

The efficacy delta is large and fast-acting, and the SAEs may be rare and not necessarily predictive of broader tolerability if causality is clarified.

Key entities

  • Helus Pharma

    Reported Phase 3 APPROACH results for HLP003 in MDD and disclosed three treatment-related serious adverse events.

  • HLP-003 (HLP003)

    Deuterated psilocin therapy candidate evaluated in the Phase 3 APPROACH trial for major depressive disorder.

  • APPROACH

    Late-stage Phase 3 trial in moderate-to-severe major depressive disorder; results included efficacy endpoints and SAE disclosures.

Related articles

$HELPMed

HELP Stock Slides As Suicide Attempt Overshadows Strong Late-stage Depression Trial Data

HELP stock declined despite positive late-stage trial data for its depression drug, HLP003. The drug showed significant improvements in patients, with 56% seeing at least a 50% improvement at six weeks. Analysts like Lucid Capital raised their price target to $79, citing strong results, while Jefferies and Barclays maintained 'Buy' and 'Overweight' ratings, respectively. Retail sentiment on Stocktwits turned 'extremely bullish'.

$HELPMedAI 8/10

Helus Pharma falls 10.5% despite positive HLP003 trial

Helus Pharma (HELP) reported positive results for its experimental drug HLP003, meeting the primary endpoint in a late-stage depression trial. Despite this, shares fell 10.5% to $7.94, with three serious adverse events disclosed. Analysts noted strong efficacy and no fundamental reason for the decline. The company is also developing HLP004 for anxiety and expects to identify an HLP005 candidate in late 2027.

HighAI 8/10

Helus Pharma's psychedelic depression drug succeeds in late-stage study, shares jump

Helus Pharma reported that its psychedelic drug, HLP003, showed significant improvement in depression symptoms in a late-stage trial. The drug, a modified version of psilocin, is designed to be used with standard antidepressants. The company's shares rose over 20% in premarket trading. According to Helus, 56.3% of patients treated with HLP003 saw their symptoms cut by at least half, compared with 28.2% on placebo.